Cargando…
Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905072/ https://www.ncbi.nlm.nih.gov/pubmed/35278742 http://dx.doi.org/10.1016/j.ebiom.2022.103899 |
| _version_ | 1784665113244991488 |
|---|---|
| author | Anderson, David A. Godfrey, Dale I. |
| author_facet | Anderson, David A. Godfrey, Dale I. |
| author_sort | Anderson, David A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8905072 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89050722022-03-09 Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ Anderson, David A. Godfrey, Dale I. EBioMedicine Letter Elsevier 2022-03-09 /pmc/articles/PMC8905072/ /pubmed/35278742 http://dx.doi.org/10.1016/j.ebiom.2022.103899 Text en © 2022 Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Letter Anderson, David A. Godfrey, Dale I. Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ |
| title | Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ |
| title_full | Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ |
| title_fullStr | Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ |
| title_full_unstemmed | Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ |
| title_short | Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’ |
| title_sort | letter to the editor re: lake et al., 2022 comment on fulford et al., 2021 ‘a point-of-care lateral flow assay for neutralizing antibodies against sars-cov-2’ |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905072/ https://www.ncbi.nlm.nih.gov/pubmed/35278742 http://dx.doi.org/10.1016/j.ebiom.2022.103899 |
| work_keys_str_mv | AT andersondavida lettertotheeditorrelakeetal2022commentonfulfordetal2021apointofcarelateralflowassayforneutralizingantibodiesagainstsarscov2 AT godfreydalei lettertotheeditorrelakeetal2022commentonfulfordetal2021apointofcarelateralflowassayforneutralizingantibodiesagainstsarscov2 |